Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy

Sinead E. Morris¹, Renate Strehlau², Stephanie Shiau³, Elaine J. Abrams^{4,5,6}, Caroline T. Tiemessen⁷, Louise Kuhn^{4,8}, Andrew J. Yates¹, on behalf of the EPIICAL Consortium and the LEOPARD study team

¹Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA ²Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa ³Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, 08854, USA ⁴Department of Epidemiology, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁵ICAP at Columbia University, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁶Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University Medical Center, New York, NY, USA

⁷Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services, and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

⁸Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA

Abstract

In 2019 there were 490,000 children under five living with HIV. Understanding the dynamics of HIV suppression and rebound in this age group is crucial to optimizing treatment strategies and increasing the likelihood of infants 2 achieving and sustaining viral suppression. Here we studied data from a cohort of 122 perinatally-infected 3 infants who initiated antiretroviral treatment (ART) early after birth and were followed for up to four years. These data included longitudinal measurements of viral load (VL) and CD4 T cell numbers, together with information regarding treatment adherence. We previously showed that the dynamics of HIV decline in 53 of these infants 6 who suppressed VL within one year were similar to those in adults. However, in extending our analysis to all 122 infants, we find that a deterministic model of HIV infection in adults cannot explain the full diversity in infant 8 trajectories. We therefore adapt this model to include imperfect ART adherence and natural CD4 T cell decline and reconstitution processes in infants. We find that individual variation in both processes must be included 10 to obtain the best fits. We also find that, perhaps paradoxically, infants with faster rates of CD4 reconstitution 11 on ART were more likely to experience resurgences in VL. Overall, our findings highlight the importance of 12 combining mathematical modeling with clinical data to disentangle the role of natural immune processes and 13 viral dynamics during HIV infection. 14

15 Keywords: HIV, infants, ART, mathematical model, viral dynamics, rebound, latent reservoir

HIV resurgence in infants on ART 2

16 Author Summary

For infants infected with HIV at or near birth, early and continued treatment with antiretroviral therapy (ART) 17 can lead to sustained suppression of virus and a healthy immune system. However many treated infants experience viral rebound and associated depletion of CD4 T cells. Mathematical models can successfully capture 19 the dynamics of HIV infection in treated adults, but many of the assumptions encoded in these models do not 20 apply early in life. Here we study data from a cohort of HIV-positive infants exhibiting diverse trajectories in 21 response to ART. We show that wide-ranging outcomes can be explained by a modified, but still remarkably 22 simple, model that includes both the natural dynamics of their developing immune systems and variation in 23 treatment adherence. Strikingly, we show that infants with strong rates of recovery of CD4 T cells while on ART 24 may be most at risk of virus resurgence. 25

²⁶ Introduction

In 2019 there were 490,000 children under five living with HIV, and 150,000 newly diagnosed cases [1]. Al-27 though infants receiving antiretroviral treatment (ART) can suppress viral load (VL), eventually the cessation 28 of treatment leads to HIV rebound, due to reactivation of latently-infected cells. Nevertheless, early initiation of 29 ART can lead to extended periods of suppression in the absence of treatment - for example, over 22 months in 30 the case of the 'Mississippi Child' and 8.75 years in a South African participant of the Children with HIV Early 31 antiRetroviral therapy (CHER) trial [2, 3]. Therefore, understanding the dynamics of HIV suppression and re-32 bound following ART initiation in young infants is crucial for optimizing treatment strategies and increasing 33 the likelihood of achieving and sustaining viral suppression. 34

We previously showed that a simple biphasic model of VL decay captures the early dynamics of HIV decline in 35 perinatally-infected infants on ART and that these dynamics are similar to those in adults [4]. However, mod-36 els applied to dynamics of infection in adults over longer timescales typically encode assumptions that do not 37 extend to infants [5-12]. First, CD4 T cell dynamics in adults are typically described as a balance between a 38 constant total rate of influx and a constant per capita rate of loss, leading to steady trajectories in the absence of 39 infection. In contrast, HIV-uninfected infants experience a natural, exponential decline in CD4 T cell numbers 40 per unit volume of blood as the immune system matures [13]. Second, perinatally-infected infants undergo a 41 transient period of CD4 T cell reconstitution upon ART initiation, during which numbers quickly recover to 42 those of HIV-uninfected infants [14]. This short-lived process cannot be captured by the constant CD4 recruit-43 ment term exploited in many models of adult infection. Third, the standard assumption that ART is completely 44 effective in blocking new infection of cells may not hold true for young infants, due to challenges in treatment 45 adherence. Thus, canonical models of HIV suppression and rebound in adults must be modified for infants to 46 include potential reductions in ART efficacy, and more complex dynamics of CD4 T cell numbers. 47 Here we model the dynamics of HIV infection in a cohort of perinatally-infected infants from Johannesburg, 48

49 South Africa who initiated ART early in life. We extend a simple deterministic model of HIV suppression and

⁵⁰ rebound in adults to incorporate incomplete treatment adherence and dynamics of natural CD4 T cell decline

⁵¹ and reconstitution. By fitting this model to longitudinal viral RNA and CD4 T cell data, we estimate rates of

⁵² reactivation and reconstitution. We also show that individual variation in CD4 reconstitution rates are an im-

HIV resurgence in infants on ART 3

- ⁵³ portant factor driving variation in HIV suppression and resurgence characteristics across infants, in addition to
- 54 ART adherence. Overall, our results demonstrate the complex interplay between natural immune processes and
- ⁵⁵ HIV dynamics, and highlight the importance of mathematical modeling in disentangling these factors.

56 Methods

57 Data

⁵⁸ The LEOPARD study has been described previously [4, 15]. Briefly, 122 perinatally-infected infants were en-

rolled at the Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa, between 2014 and 2017.

⁶⁰ The majority began ART within two weeks of birth (median age: 2.5 days; interquartile range (IQR): 1–8), and

were followed for up to four years. VL (HIV RNA copies ml⁻¹) and CD4 T cell concentrations (cells μ l⁻¹) in the blood were sampled over time, and various clinical covariates were also recorded, including the infant's

the blood were sampled over time, and various clinical covariates were also recorded, including the infants pre-treatment CD4 percentage, the mother's VL and CD4 count after delivery, and the mother's prenatal ART

⁶³ pre-treatment CD4 percentage, the mother's VL and CD4 count after delivery, and the mothe
 ⁶⁴ history (full list in Table S1).

⁶⁵ With these data, we previously identified a subset of 53 infants who successfully suppressed VL within one

 $_{66}$ year [4, 16], with suppression defined as having at least one VL measurement below the 20 copies ml⁻¹ detection

⁶⁷ threshold of the RNA assay. Here, we are interested in the interplay between natural CD4 T cell dynamics and

⁶⁸ infection processes, and whether and how this interplay determines whether an infant achieves suppression

⁶⁹ and/or experiences VL rebound. We have therefore broadened our analysis to all 122 infants.

In addition to the data described previously, we include information relating to ART adherence that was obtained 70 at each study visit (details in SI). For each drug in each infant's ART regimen - with the recommended, and most 71 common, being zidovudine (AZT), lamivudine (3TC), and (i) nevirapine (NVP) in the first four weeks of treat-72 ment, then (ii) ritonavir-boosted lopinavir (LPV/r) after four weeks - we estimated a percentage adherence by 73 comparing the weight of medicine returned to the expected amount returned assuming perfect adherence. Less 74 than 100% adherence can result from missed doses or 'under-dosing' (giving too little medicine at each dose), 75 whereas greater than 100% adherence can occur through over-dosing or problems with drug tolerance (infants 76 may spit up bad-tasting medicine, therefore requiring repeat dosing). For many visits, adherence could not be 77 calculated because leftover medicine was not returned. The adherence estimates are therefore influenced by 78 many unobserved factors and, given uncertainty in how the quantitative estimates map to actual adherence, we 79 instead defined a categorical variable that labeled adherence estimates greater than 90% as 'good', and estimates 80 less than 90% as 'poor'. Using 85% and 95% as alternative thresholds for good adherence did not alter our find-81 ings. With this course-grained approach, some missing values could be manually labelled based on physician 82 commentary from accompanying questionnaires (for example, if substantial gaps in dosing were noted, adher-83 ence was labeled as poor). We then summarized the average adherence of each infant as the most frequently 84 reported category (good or poor) across their time series. 85

86 Ethics statement

87 All protocols for the LEOPARD study were approved by the Institutional Review Boards of the University of the

88 Witwatersrand and Columbia University. Written informed consent was obtained from mothers for their own

HIV resurgence in infants on ART 4

⁸⁹ and their infants' participation.

90 Model

We describe HIV dynamics in an infant on ART using a deterministic ordinary differential equation (ODE) 91 model (Fig 1A) [7, 12]. We assume that CD4 target cells, T(t) (measured as the concentration of cells per μl 92 of blood, but from here on referred to as 'cells' or 'counts' for brevity), undergo background growth and loss 93 according to a function $\theta(t, T)$, and are infected by free virus, V(t), at *per capita* transmission rate β (Table 1). 94 During ART this transmission is blocked with efficacy ϵ_1 , where $\epsilon_1 < 1$ reflects incomplete adherence of reverse 95 transcriptase inhibitor drugs that block infection of new cells (for example, NVP and AZT). A proportion $(1 - \rho)$ 96 of the newly infected target cells seed the latent reservoir; the remaining fraction, ρ , either become productively 97 infected or die through abortive infection [17]. Cells from this heterogeneous infected population, I(t), are lost 98 at an average rate d, and produce virus at an average rate $(1 - \epsilon_2)p$, where p subsumes the fraction of cells that 99 are productively infected and $\epsilon_2 < 1$ reflects any failure of protease inhibitors (for example, LPV/r) to block the 100 production of infectious virus. The infected cell population is also boosted by reactivation of the latent reservoir, 101 at rate a. We do not explicitly model the number of latently infected cells due to uncertainties in the rates of 102

¹⁰³ proliferation and loss in this population, and a lack of available data to estimate these parameters. Finally, free

virus is lost at rate c. This system can be represented by the following equations

$$\frac{dT}{dt} = \theta(t,T) - (1-\epsilon_1)\beta VT$$
$$\frac{dI}{dt} = \rho(1-\epsilon_1)\beta VT - dI + a$$
$$\frac{dV}{dt} = (1-\epsilon_2)pI - cV.$$

¹⁰⁵ The reproduction number for this model at ART initiation is

$$R_0 = \frac{\rho(1-\epsilon_1)(1-\epsilon_2)\beta pT_0}{cd},$$

where T_0 is the initial CD4 count (assuming contribution from the latent reservoir is negligible at this time).

¹⁰⁷ In the simplest case we assume all rate parameters are constant over time. However, we also investigate an ¹⁰⁸ extension of this model that incorporates a delay in reactivation of the latent reservoir,

$$a = \begin{cases} 0 & \text{if } t \le T_A \\ \bar{a} & \text{if } t > T_A, \end{cases}$$

where T_A is the time to reactivation in days. Assuming the rate of virus turnover is faster than that of CD4 T

cells [18], we reduce the model to the following system

HIV resurgence in infants on ART 5



Figure 1: Model framework and analysis schematic. (A) Framework for the infection model with rate constants. CD4 target cells (T) are infected by free virus (V) and either become productively infected cells (I) or latently infected cells. Productively infected cells produce free virus whereas latently infected cells do not; but latently infected cells can become reactivated at a later point to join the productively infected cell population. CD4 target cells also undergo reconstitution and natural decline processes according to $\theta(t, T)$. Further details are given in the text. (B) Schematic illustrating the definition of viral resurgence (top) compared to no resurgence (bottom). The timing of resurgence is defined as the time at which VL first starts increasing (vertical red line), and the size of resurgence is the total integrated VL during the upslope period (blue shaded region). The dashed horizontal line represents the assay detection threshold.

$$\frac{dT}{dt} = \theta(t,T) - \beta_0 V T$$
$$\frac{dV}{dt} = \rho \bar{c} \beta_0 V T - dV + a \bar{c},$$

where $\beta_0 = (1 - \epsilon_1)\beta$ and $\bar{c} = (1 - \epsilon_2)p/c$ (derivation in the SI). The compound parameter \bar{c} represents the contribution of each infected cell to the total viral load, through its rate of production of virions and the average time they persist in circulation. Both β_0 and \bar{c} incorporate ART efficacy (through ϵ_1 and ϵ_2), and thus infant ART adherence.

Finally, we extend the model for young infants through the term governing background CD4 T cell growth and loss, $\theta(t, T)$. In models of infection dynamics in adults, $\theta(t, T)$ typically takes the form $\lambda - d_T T$, where λ and d_T are constant rates representing cell influx and natural decay processes, respectively. These forms lead to steady trajectories in the absence of infection. For infants, we propose an alternative $\theta(t, T)$ that instead accounts for (i) the exponentially declining concentration of CD4 T cells that is observed as HIV-uninfected infants age [13], and (ii) the transient recovery in CD4 counts experienced by HIV-infected infants during the early stages of ART [14]. First, the natural decline in CD4 T cells can be captured by an exponential decay function

HIV resurgence in infants on ART 6

$$T = c_0 + b_0(1 - e^{b_1 t})$$

where c_0 , b_0 and b_1 are constant parameters that have been independently estimated in a cohort of 80 uninfected

children in Germany, including 39 aged between 2 months and 4 years [13]. This function also captured CD4

¹²⁴ T cell dynamics in 381 South African children, of whom 300 were aged between 2 weeks and 5 years [19].

¹²⁵ Second, the additional reconstitution of the CD4 T cell pool in HIV-infected infants can be modeled as a transient

¹²⁶ increase in cell counts during the early stages of ART, i.e.

$$\frac{dT}{dt} = \begin{cases} r & \text{if } t \le T_R \\ 0 & \text{if } t > T_R, \end{cases}$$

where r is the constant rate of reconstitution and T_R is the time to reach healthy levels [14]. Combining these

processes of reconstitution and the natural decline of CD4 T cell counts in infants gives $\theta(t,T) = -b_1 b_0 e^{b_1 t} + \bar{r}$,

129 and

$$\frac{dT}{dt} = -b_1 b_0 e^{b_1 t} + \bar{r} - \beta_0 V T \tag{1}$$

$$\frac{dV}{dt} = \rho \bar{c} \beta_0 V T - dV + a \bar{c},\tag{2}$$

130 where

$$\bar{r} = \begin{cases} r & \text{if } t \le T_R \\ 0 & \text{if } t > T_R. \end{cases}$$

¹³¹ Model fitting and comparisons

We fit equations 1 and 2 to the VL and CD4 T cell data from all 122 infants using a nonlinear mixed effects 132 approach. All VL observations below the detection threshold were treated as censored values, and we assumed 133 both V(t) and T(t) were lognormally distributed [20, 21]. Given the relative infrequency of CD4 T cell mea-134 surements, we fixed four parameters across all individuals (Table 1): three that governed the reconstitution and 135 natural dynamics of target cells (T_R , b_0 and b_1), and the proportion of newly infected cells that become pro-136 ductively infected (ρ). All other parameters were estimated and allowed to have both fixed and random effects. 137 In subsequent analyses we estimated fixed and random effects for T_R . We also examined the importance of 138 individual variation in adherence and CD4 T cell recovery by comparing the best fit model to three alternative 139 models in which β_0, \bar{c} or r were fixed across all infants. 140

HIV resurgence in infants on ART 7

Following exploratory fits, each estimated parameter was assumed to follow a lognormal distribution, with the 141 exception of a which followed a logit-normal distribution with pre-specified upper bound, and T_R which 142 followed normal distributions. We verified that the random effects for all estimated parameters were normally 143 distributed, using the Shapiro-Wilk test. Guided by the exploratory fits, we allowed β_0 and d to be correlated, 144 and assumed all other parameters were independent. We confirmed the identifiability of all parameters [22], and 145 conducted additional sensitivity analyses by varying each chosen parameter in turn and re-simulating the model, 146 while keeping all other parameters fixed. We used these simulations to assess the sensitivity of model predic-147 tions to our choice of fixed parameters. Model fitting and parameter estimation were implemented in Monolix 148 2020R1 [21]. Downstream analyses and plotting were conducted in R version 4.03 [23], with the deSolve, 149 cowplot, patchwork and tidyverse packages [24-27]. All details needed to reproduce our analyses are 150

¹⁵¹ given in the SI.

Parameter	Description	Units	Value,	Mean (SE),
			if fixed	if estimated*
$\beta_0 = (1 - \epsilon_1)\beta$	Per-cell effective transmission rate	$(\text{copies ml}^{-1})^{-1} \text{ day}^{-1}$		$5(1) \times 10^{-8}$
ρ	Proportion of cell infections that are productive	-	0.9999 [5, 28]	
$\bar{c} = (1 - \epsilon_2)p/c$	Ratio of viral production to loss	$copies ml^{-1} cell^{-1}$		220 (76)
d	Rate of infected cell loss	day^{-1}		0.05 (0.006)
a	Total rate of latent reservoir reactivation	cells day $^{-1}$		0.001 (0.001)
b_0	Extent of natural CD4 T cell decline	cells	-2354 [13]	
$-1/b_1$	Timescale of natural CD4 T cell decline	days	1003 [13]	
r	Rate of CD4 T cell reconstitution	cells day ⁻¹		8.0 (0.4)
T_R	Age at reconstitution plateau	days	170-300 [†] [14]	
T_0	Initial number of CD4 T cells	cells		1612 (80)
V_0	Initial viral load	copies ml^{-1}		5077 (1259)

Table 1: Model parameters and population-level estimates.

*Estimates taken from the model with lowest AIC.

[†]A range of values were explored around previous estimates [14].

SE = standard error (random effect) around the population mean (fixed effect); cells = cells μl^{-1} .

We compared the statistical support for different models using the Akaike Information Criterion (AIC). For 152 model i, AIC_i = $2k - 2 \ln L$, where k is the number of estimated parameters, $\ln L$ is the maximum log-153 likelihood, and lower AIC values indicate stronger statistical support. We assessed the relative support for model 15 *i* using $\Delta AIC_i = AIC_i - AIC_{min}$, where AIC_{min} is the minimum AIC value across all models. Differences greater 155 than five indicate substantially greater support for the model with $AIC_i = AIC_{min}$. For the favored model, we 156 used the individual-specific parameter estimates to predict VL and CD4 T cell trajectories for each child. These 157 trajectories extended either to the end of our study period or two years after their last observation, whichever 158 was earlier. We then compared how viral infection and the natural decline in CD4 T cells mediated the overall 159 VL and CD4 T cell dynamics. We calculated the relative contributions of new viral infection and natural decline 160 to decreases in CD4 T cell numbers as 161

$$\frac{\beta_0 TV}{\beta_0 TV + b_1 b_0 e^{b_1 t}} \quad \text{and} \quad \frac{b_1 b_0 e^{b_1 t}}{\beta_0 TV + b_1 b_0 e^{b_1 t}},\tag{3}$$

162 respectively. Similarly, the relative contributions of new viral infection and latent reservoir reactivation to in-

HIV resurgence in infants on ART 8

¹⁶³ creases in the number of productively infected cells were

$$\frac{\rho\beta_0 TV}{\rho\beta_0 TV + a} \quad \text{and} \quad \frac{a}{\rho\beta_0 TV + a},\tag{4}$$

164 respectively.

165 Statistical analyses

- ¹⁶⁶ We tested for statistical associations between model parameters, clinical covariates (Table S1), and the risk of
- ¹⁶⁷ VL resurgence defined as any predicted increase in VL following initiation of ART (Fig 1B). We chose VL
- resurgence as our indicator of imperfect viral control rather than VL rebound (any predicted increase in VL
- ¹⁶⁹ following initial suppression of HIV) due to the small number of infants experiencing the latter (5/122 infants ¹⁷⁰ experienced rebound compared to 52/122 experiencing resurgence). We defined the timing of VL resurgence as
- experienced rebound compared to 52/122 experiencing resurgence). We defined the timing of VL resurgence as
 the first point at which the model predicted an increase in VL, and the size of resurgence as the total integrated VL
- the first point at which the model predicted an increase in VL, and the size of resurgence as the total integrated VL during the upslope period (Fig 1B). We then tested for associations using Spearman correlations between pairs of
- during the upslope period (Fig 1B). We then tested for associations using Spearman correlations between pairs of quantitative variables, the Kruskal Wallis test between quantitative and categorical variables, and Chi-squared
- tests between pairs of categorical variables. We adjusted for multiple testing using the Benjamini-Hochberg
- 175 correction.

176 **Results**

The model for adult infection, with $\theta(t,T) = \lambda - d_T T$, was a poor fit to the infant data, particularly the 177 CD4 T cell counts (Fig S1, Table 2). We therefore used the model adapted for infant infection, with $\theta(t,T) =$ 178 $-b_1b_0e^{b_1t} + \bar{r}$, in all further analyses. First, we verified that the infant model with fixed time to reconstitution 179 plateau, T_R , and constant rate of latent reactivation, a, was structurally identifiable (see Table 1 and SI) [22]. We 180 initially fixed $T_R = 225$ days across all infants, following previous modeling of CD4 reconstitution in another 181 cohort of HIV-infected infants who initiated ART 82 days after birth, on average [14]. We refitted the model with 182 different fixed values and verified that the best fits were obtained when $T_R = 225$ days ($\Delta AIC_i = 8.3$ relative 183 to the next best model with T_R = 223 days; Table S2). Including random effects for T_R improved model fits, 184 although also estimating the fixed effect (i.e. estimating the population average of T_R) did not (Table 2). This is 185 likely due to the increased complexity introduced by estimating an additional parameter. Similarly, including a 186 delay in reactivation of the latent reservoir did not improve model fits. We therefore focus on the model with a 187 constant rate of reactivation from the latent reservoir and random effects for T_R around a predefined population 188 mean of 225 days. With this model, VL predictions were marginally sensitive to all fixed parameters (T_R , b_0 , 189 b_1 and ρ ; Fig S2), whereas CD4 T cell dynamics were sensitive to those governing healthy T cell reconstitution 190 and decline $(T_R, b_0 \text{ and } b_1)$ but robust to changes in the proportion of new infections that become productively 191 infected cells (ρ ; Fig S3). 192 Strikingly, our relatively simple deterministic model captured the wide variation in infant VL trajectories, in-193

cluding monotonic decreases to suppression, eventual suppression following transient increases in VL, and brief 194 periods of suppression with a subsequent rebound in VL (Fig 2). Later, or multiple, rebound occurrences were 195 generally not so well captured. These behaviors may be due to repeated fluctuations in treatment adherence 196 or stochastic processes driving delayed reactivation of the latent reservoir, neither of which are included in the 197 model. Initially, new infections were the major contributor to growth of the productively infected cell pop-198 ulation (Eqn 4; Fig S4). However, in almost all infants the importance of new infection events was eventually 199 superseded by reactivation from the latent reservoir, although this displacement was delayed by viral resurgence 200 events and prolonged CD4 T cell recovery (Fig S5). 201

Table 2: Model comparisons. AIC values (Δ AIC) are quoted relative to the minimum AIC value across all models. The model with Δ AIC = 0 is the model with lowest AIC and thus has most statistical support. See Table 1 for parameter definitions.

Model*	ΔAIC
Constant <i>a</i> ; fixed $T_R = 225$ days with random effect	0.0
Constant <i>a</i> ; fixed $T_R = 225$ days without random effect	7.1
Constant a ; estimated T_R	27.1
Time-varying a , fixed $T_R = 225$ days without random effect	31.5
$\theta(t,T) = \lambda - d_T T$	365.4

*Unless stated otherwise, $\theta(t,T) = -b_1 b_0 e^{b_1 t} + \bar{r}$.

The majority of infants experienced a transient increase in CD4 T cell counts followed by a steady decline; these patterns were well captured by the model (Fig 3). The decline in CD4 T cells was almost always driven by

HIV resurgence in infants on ART 10



Figure 2: **Model fits for RNA observations** Each panel represents a different infant; points represent the data; and solid lines are the model fits. The dashed horizontal line is the detection threshold of the RNA assay, and red crosses are censored observations below this threshold. Panels shaded in red are infants who experienced viral resurgence (i.e. at least one period of increasing VL).

HIV resurgence in infants on ART 11

natural processes, although the contribution of new infections increased during periods of VL resurgence (Eqn 3;
 Fig S6).

The fixed effects for all estimated parameters, and the standard error of the associated random effects, are given in 206 Table 1. The population-level average lifespan of productively infected cells (1/d) was 19 days (95% percentile 207 across all infants = 5-52 days), and R_0 at ART initiation was 0.35 (0.18–1.25), reflecting an initial decrease 208 in VL across most infants. The rate of CD4 T cell reconstitution, r, was positively correlated with the initial 209 number of CD4 T cells, T_0 , and the duration of reconstitution, T_R (Fig S7). These associations are unlikely to be 210 driven by poor parameter identifiability, which would instead cause negative correlations through compensatory 211 mechanisms. Notably, we found that infants with higher reconstitution rates, r, and VL production to decay 212 ratios, \bar{c} , were more likely to experience increases in VL after ART initiation ($p < 1 \times 10^{-4}$; Fig 4A–B), although 213 the effect was small in the former case (difference in means = 1.2% of the population average). For those infants 214 who did experience increases in VL, larger and earlier increases were associated with higher VL production to 215 decay ratios ($p < 1 \times 10^{-4}$; Fig 4C–D), but not reconstitution rates (p > 0.5). Overall, these results suggest that 216 VL production to decay ratios and CD4 reconstitution rates are the most important parameters determining an 217 infant's resurgence characteristics. 218

In addition to the deterministic model parameters, we found a longer duration of maternal prenatal ART was associated with risk of VL resurgence (p < 0.01; Fig 4E). However, this covariate was also associated with higher VL production to decay ratios (p < 0.01; Fig S9), suggesting potential colinearity. All other associations between VL resurgence characteristics and clinical covariates, including pre-treatment CD4 percentage and age at ART initiation (Table S1), were not significant at the p = 0.05 level. Taken together, these findings suggest maternal prenatal ART history may mediate the risk of VL resurgence, through, or in addition to, the deterministic model parameters discussed above.

Variation in both adherence and the natural dynamics of CD4 T cells dictate infant trajec tories

The most obvious explanation for the wide variety of VL suppression and resurgence trajectories we have iden-228 tified here is variation in ART adherence, which may be more pronounced in infants than adults. In our models, 220 we assume variation in ART adherence is reflected entirely in the parameters ϵ_1 and/or ϵ_2 , which dictate the 230 efficiency of treatment at blocking new infection and virus production by infected cels, respectively. These pa-231 rameters are not individually identifiable with these data, but instead are subsumed in the compound parameter 232 $\bar{c} = (1 - \epsilon_2)p/c$ and $\beta_0 = (1 - \epsilon_1)\beta$. (In support of this, we found that \bar{c} was associated with our measures of 233 LPV/r, NVP and AZT adherence from the study questionnaires (p<0.05, Fig 4F), although β_0 was not.) Thus, 234 if adherence is the main driver of variation in VL trajectories, then individual variation in \bar{c} and β_0 should be 235 the most crucial components of our model. However, the association we detected between CD4 reconstitution 236 rates and the probability of resurgence suggest variation in CD4 T cell dynamics may also be important. To 237 explore this issue, we refit the model while removing the random effects for β_0 , \bar{c} and r in turn. We found that 238 fixing any of these parameters resulted in poorer fits, although the model with fixed r performed worst overall 239 (Table 3). This suggests that CD4 T cell dynamics are an important factor driving variation in HIV suppression and resurgence characteristics across infants, in addition to ART adherence. 241

HIV resurgence in infants on ART 12



Figure 3: Model fits for CD4 T cell observations Each panel represents a different infant, ordered as in Fig 2; points represent the data; and solid lines are the model fits.

HIV resurgence in infants on ART 13



Figure 4: VL resurgence is associated with CD4 reconstitution, VL production and decay, and ART history of infant and mother. (A–B) Relationship between the occurrence of VL resurgence (defined as any increase in VL following initiation of ART) and the CD4 reconstitution rate, r, in cells μ l⁻¹ day⁻¹ (A) and ratio of VL production to decay, $\bar{c} = (1 - \epsilon_2)p/c$, in copies ml⁻¹ cell⁻¹ (B). Each point represents a different infant and $p < 0.0001(^{****})$ in both cases. Five infants whose resurgence was a viral rebound event are highlighted in orange. (C–D) Relationship between \bar{c} and the size of VL resurgence in RNA copies ml⁻¹ (C) and timing of VL resurgence in days (D). Each point represents an infant who experienced resurgence. Correlations are 0.61 and -0.58, respectively, and $p < 1 \times 10^{-4}$ in both cases. (E) Relationship between the occurrence of VL resurgence and the timing of maternal prenatal ART initiation (p < 0.01). The size of each box reflects the proportion of infants in the corresponding category and the numbers show the corresponding sample size. (F) Relationship between infant ART adherence is associated and VL production to decay ratios. Adherence was classified as 'good' if the majority of adherence estimates were 90% or more, and 'poor' otherwise. The VL production to decay ratio is given by $\bar{c} = (1 - \epsilon_2)p/c$, in copies ml⁻¹ cell⁻¹. Each panel represents a different drug and each point represents a different infant. Significance levels are $p < 0.05(^*)$; $p < 0.01(^{**})$.

Table 3: Model comparisons of adherence and CD4 recovery parameters. AIC values (Δ AIC) are quoted relative to the minimum AIC value across all models. The model with Δ AIC = 0 is the model with lowest AIC and thus has most statistical support. See Table 1 for parameter definitions.

Model	ΔAIC
Fixed and random effects for β_0, \bar{c} and r^*	0.0
Fixed and random effects for \bar{c} and r ; only fixed effects for β_0	30.0
Fixed and random effects for β_0 and r ; only fixed effects for \bar{c}	31.9
Fixed and random effects for β_0 and $\bar{c};$ only fixed effects for r	79.6
to a many and the third base of the model in Table 2	

Corresponds to the best-fit model in Table 2.

HIV resurgence in infants on ART 14

242 Discussion

In this study we modeled the dynamics of HIV suppression and rebound in perinatally-infected infants receiving ART. Our framework extends previous models of rebound in adults [7, 12] by incorporating mechanisms of the natural decline and infection-induced reconstitution of CD4 T cells in young infants [14]. We found that new infection events were initially the major contributor to growth of the productively infected cell population, but that reactivation of the latent reservoir became more important once VL levels were low (Fig S4). We also

- ²⁴⁸ identified natural processes as the longterm driver of CD4 T cell declines in blood.
- Although our estimates of the average CD4 T cell reconstitution rate (r = 8 cells μ l⁻¹ day⁻¹) is greater than
- those from another cohort of HIV-infected infants (r = 3.8 cells μ l⁻¹ day⁻¹), it is within the interquartile ranges.
- 251 Notably, infants from this other cohort initiated ART later, on average, than the infants in our cohort (median
- ²⁵² = 82 days, IQR = 34–121), and all eventually achieved viral suppression [14]. We also found that higher rates
- of reconstitution were associated with a greater probability of experiencing a resurgence in VL. This relation-
- ship was not confounded by the immunological status of infants at the beginning of the study as we found no
- association between the reconstitution rate and pre-treatment CD4 percentage or counts, or between the risk
- of VL resurgence and pre-treatment CD4 percentage or counts. Our finding raises the possibility that rapid re-
- 257 covery of CD4 T cells, despite suggesting an improved clinical state, can also increase the risk of VL resurgence
- in some individuals by repopulating the target cell pool. Although it could also be that VL resurgence triggers
- ²⁵⁹ more rapid CD4 reconstitution through increased anti-viral immune activity or density-dependent responses to
- ²⁶⁰ CD4 depletion [14], the latter seems unlikely in this cohort as we did not detect a negative association between
- the initial number of CD4 T cells (T_0) and r. Nevertheless, further investigation is needed to determine the
- directionality of this relationship, and whether the extent of CD4 T cell recovery may be used as a biomarker for
- ²⁶³ individuals at increased risk of VL resurgence.

We also found that higher ratios of VL production to decline, \bar{c} , were associated with a greater risk of resurgence, 264 and larger and earlier increases in VL given that resurgence occurred. This is perhaps to be expected given that 265 \bar{c} effectively controls the amount of free virus available to infect new cells at any given time. The association 266 between \bar{c} and LPV/r adherence is also expected given that \bar{c} is a function of the protease inhibitor efficacy, 267 ϵ_2 . However, the additional associations with AZT and NVP adherence suggest \bar{c} is also capturing some of 268 the variation in reverse transcriptase inhibitor adherence through virus availability and its downstream effects 269 on cell infection rates. Finally, although we cannot isolate the contribution of drug resistance to the protease 270 inhibitor efficacy, we expect that resistance to LPV/r is rare in this cohort and is thus unlikely to be a major 271 driver of individual variation in \bar{c} , or of VL resurgence patterns. 272

Our estimate of another key parameter, the rate of latent cell reactivation ($a = 10^{-3}$ cells μ l⁻¹ day⁻¹), is at the 273 upper limit of similar estimates from adults obtained during ART interruption $(2 \times 10^{-6} - 1 \times 10^{-3} \text{ cells})$ 274 μ ¹ day⁻¹ [7]). Biologically, a higher burden of reactivation (a) may reflect a larger latent reservoir in these 275 infants and/or an increased per-cell rate of latent cell reactivation. Dynamically, larger reactivation estimates 276 may compensate for significant fluctuations in treatment adherence that are not included in the model. We 277 did not find any associations between a and the occurrence or size of VL resurgence. This is not surprising as 278 a effectively represents the total contribution of latent cell reactivation averaged over the entire study, and its 279 contribution to changes in VL relative to those of de novo infection events is small (Eqn. 2). 280

HIV resurgence in infants on ART 15

One unexpected result is that our simple framework can capture large variations in infant VL trajectories, in-281 cluding monotonic decreases to sustained suppression, resurgences in VL, and suppression with subsequent re-282 bound. Although the canonical explanation for erratic VL patterns is imperfect ART adherence, we found that 283 incorporating variation in CD4 reconstitution rates was also required to capture the complexity in our infant 284 data. In addition, we found that longer durations of maternal prenatal ART were associated with VL resurgence, 285 which is consistent with findings from this cohort that exposure to maternal prenatal ART is associated with a 286 larger viral reservoir [29], and could not be explained by worse adherence in this group (p > 0.2). However, we 287 could not disentangle the effects of this variable from that of VL production to decay ratios, \bar{c} . Netherless, our 288 findings demonstrate that a deterministic framework with reactivation and constant ART efficacy can recapit-289 ulate intricate infection dynamics, and that, with the levels of adherence achieved in this study, resurgence may 290

²⁹¹ in fact be inevitable for infants with certain virological and CD4 T cell parameter combinations.

There are a number of caveats to our modeling approach. First, our model does not differentiate between short-292 and long-lived productively infected cells, the loss of which underpins the multiphasic decline of VL in adults 293 and infants on ART [4, 30, 31], or cells that have undergone abortive infection [17]. Instead, our estimates of 294 the mean lifespan of an infected cell is effectively a weighted average of the mean lifespans of these subpopula-295 tions. Although our averaged estimate (19 days) is longer than corresponding values in adults (0.5–6 days) [7], 296 it agrees with the median short and long-lived cell lifespans we estimated previously in a subset of these infants 297 who achieved suppression (17 days) [4]. Second, we do not explicitly model the dynamics of latently infected 298 cells as they are not directly observed. However, the parameter a in our model is effectively a 'force of reac-299 tivation, which combines the effects of reservoir size and the per-cell rate of reactivation. Third, we do not 300 explicitly model non-productively infected cells. Although observed VL is likely a combination of infectious 301 and non-infectious virus, our results will hold if the ratio of these remains approximately constant over time for 302 each infant. Substantial and sustained changes in LPV/r efficacy (ϵ_2), for example, through prolonged shifts in 303 adherence levels and/or increasing drug resistance, may cause non-negligible changes in this ratio. However, 304 fluctuations in LPV/r adherence, although frequent, were usually transient (Fig S12), and we expect LPV/r re-305 sistance in this cohort to be rare. Nevertheless, a potentially important extension of our model would be the 306 inclusion of non-productively infected cells and/or allowing changes in LPV/r efficacy over time. Lastly, we 307 fit the peripheral CD4 T cell data to the number of target cells predicted by the model (T(t)), rather than the 308 predicted sum of target cells, productively infected cells and latently infected cells. This approach is reasonable 309 as the frequency of infection in CD4 T cells is usually small [32], and the majority of infected cells most likely 310 reside in lymphoid tissues where infection-induced CD4 depletion is greatest [33]. We also assume all CD4 T 311 cells are equally susceptible to infection, although in reality activated cells may be more susceptible than resting 312 cells [34, 35]. However, this heterogeneity is implicitly incorporated within the transmission parameter, β , if 313 the proportion of CD4 T cells that are susceptible remains approximately constant over time. 314

Finally, we acknowledge that the ART regimens used in the LEOPARD trial may not be optimal. Although considered most effective at the time of study design and implementation, more potent treatments – for example, integrase inhibitors and/or broadly neutralizing antibodies – have since been approved for young infants. It will be important to determine whether infants starting these newer treatments are also at risk of the inevitable resurgence we have identified here.

³²⁰ In conclusion, we have extended the classic framework for HIV suppression and rebound to include more realis-

HIV resurgence in infants on ART 16

- tic dynamics of CD4 T cell decline and reconstitution in young infants on ART. We estimated rates of reactivation
- and reconstitution, and identified distinct phases in which dynamics were either dominated by new infection of
- 323 CD4 T cells, or by reactivation of the latent reservoir. Moreover, we demonstrated the importance of incorpo-
- rating variation in CD4 reconstitution rates to capture the diversity of infant VL trajectories. Overall, our results
- ³²⁵ suggest that VL resurgence in perinatally-infected infants may be inevitable in certain parameter regimes, and
- ³²⁶ highlight the utility of mathematical modeling in understanding the dynamics of infant HIV infection.

HIV resurgence in infants on ART 17

327 Acknowledgements

This work is part of the EPIICAL project (http://www.epiical.org/), supported by the PENTA-ID foundation 328 (http://penta-id.org/), funded through an independent grant by ViiV Healthcare UK. Data were collected dur-32 ing the Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial (LEOPARD) study. The 330 LEOPARD study was supported in part by the Eunice Kennedy Shriver National Institute of Child Health 331 and Human Development/National Institute of Allergy and Infectious Disease, National Institutes of Health 332 (U01HD080441), USAID/PEPfAR, the South African National HIV Programme, and South African Research 333 Chairs Initiative of the Department of Science and Technology and National Research Foundation of South 334 Africa. 335 Latency and Early neOnatal Provision of Anti-Retroviral Drugs (LEOPARD) Study Team: 336

Louise Kuhn, Elaine Abrams, Wei-Yann Tsai, Stephanie Shiau (Columbia University Medical Center, New York); 337 Caroline Tiemessen, Maria Paximadis, Sharon Shalekoff, Diana Schramm, Gayle Sherman (National Institute 338 of Communicable Diseases (NICD), Johannesburg, South Africa); Renate Strehlau, Megan Burke, Martie Con-339 radie, Ashraf Coovadia, Ndileka Mbete, Faeezah Patel, Karl Technau (Empilweni Services and Research Unit 340 (ESRU), Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa); Grace Aldrovandi (Uni-341 versity of California, Los Angeles); Rohan Hazra (Eunice Kennedy Shriver National Institute of Child Health 342 and Human Development); Devasena Gnanashanmugam (National Institutes of Allergy and Infectious Dis-343 eases). 344

³⁴⁵ The EPIICAL Consortium study team:

Nigel Klein, Diana Gibb, Sarah Watters, Man Chan, Laura McCoy, Abdel Babiker (University College Lon-346 don, UK); Anne-Genevieve Marcelin, Vincent Calvez (Université Pierre et Marie Curie, France); Maria Angeles 347 Munoz (Servicio Madrileño de Salud-Hospital General Universitario Gregorio Marañon, Spain); Britta Wahren 348 (Karolinska Institutet, Sweden); Caroline Foster (Imperial College Healthcare NHS Trust, London, UK); Mark 349 Cotton (Stellenbosch University-Faculty of Medicine and Health Sciences, South Africa); Merlin Robb, Jintanat 350 Ananworanich (The Henry M. Jackson Foundation for the Advancement of Military Medicine, Maryland); Polly 351 Claiden (HIV i-Base, UK); Deenan Pillay (University of KwaZulu-Natal Africa Center, South Africa); Deborah 352 Persaud (Johns Hopkins University); Rob J de Boer, Juliane Schröter, Anet J N Anelone (University of Utrecht, 353 Netherlands); Thanyawee Puthanakit (Thai Red Cross AIDS-Research Centre, Thailand); Adriana Ceci, Viviana 354 Giannuzzi (Consorzio per Valutazioni Biologiche e Farmacologiche, Italy); Kathrine Luzuriaga (University of 355 Massachusetts Medical School, Worcester, Massachusetts); Nicolas Chomont (Centre de Recherche du Centre 356 Hospitalier de l'Université de Montreal-University of Montreal, Canada); Mark Cameron (Case Western Reserve 357 University, Cleveland, Ohio); Caterina Cancrini (Università degli Studi di Roma Tor Vergata, Italy); Andrew J 358 Yates, Louise Kuhn, Sinead E Morris (Columbia University Medical Center, New York); Avy Violari, Kennedy 359 Otwombe (University of the Witwatersrand, Johannesburg [PHRU], South Africa); Ilaria Pepponi, Francesca 360 Rocchi (Children's Hospital "Bambino Gesu", Rome, Italy); Stefano Rinaldi (University of Miami, Miller School 361 of Medicine, Florida); Alfredo Tagarro (Hospital 12 de Octubre, Universidad Complutense, Madrid, Spain); 362 Maria Grazia Lain, Paula Vaz (Fundação Ariel Glaser contra o SIDA Pediátrico, Mozambigue); Elisa Lopez, 363 Tacita Nhampossa (Fundação Manhiça, Mozambique). 364

³⁶⁵ We thank Juliane Schröter and Rob de Boer for critical reading and helpful suggestions.

HIV resurgence in infants on ART 18

366 References

- UNAIDS data; 2020. Available from: https://www.unaids.org/en/resources/documents/2020/
 unaids-data.
- Luzuriaga K, Gay H, Ziemniak C, et al. Viremic Relapse after HIV-1 Remission in a Perinatally Infected
 Child. *New England Journal of Medicine*. 2015;372(8):786–788. doi:10.1056/NEJMc1413931.
- Violari A, Cotton M, Kuhn L, et al. A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. *Nat Comm.* 2019;10(412):1–11. doi:10.1038/s41467-019-08311-0.
- 4. Morris SE, Dziobek-Garrett L, Strehlau R, et al. Quantifying the dynamics of HIV decline in perinatally-infected neonates on antiretroviral therapy. *JAIDS*. 2020;85(2):209–218. doi:10.1097/QAI.00000000002425.
- 5. Kim H, Perelson AS. Viral and Latent Reservoir Persistence in HIV-1–Infected Patients on Therapy. *PLOS Computational Biology*. 2006;2(10):1–16. doi:10.1371/journal.pcbi.0020135.
- Archin NM, Vaidya NK, Kuruc JD, et al. Immediate antiviral therapy appears to restrict resting CD4+ cell
 HIV-1 infection without accelerating the decay of latent infection. *Proceedings of the National Academy of Sciences.* 2012;109(24):9523–9528. doi:10.1073/pnas.1120248109.
- 7. Luo R, Piovoso MJ, Martinez-Picado J, et al. HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics. *PLoS One*. 2012;7(7):1–12. doi:10.1371/journal.pone.0040198.
- 8. Hill AL, Rosenbloom DIS, Fu F, et al. Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. *Proceedings of the National Academy of Sciences*. 2014;111(37):13475–13480.
 doi:10.1073/pnas.1406663111.
- 9. Petravic J, Rasmussen TA, Lewin SR, et al. Relationship between Measures of HIV Reactivation and
 Decline of the Latent Reservoir under Latency-Reversing Agents. *Journal of Virology*. 2017;91(9).
 doi:10.1128/JVI.02092-16.
- 10. Reeves DB, Duke ER, Hughes SM, et al. Anti-proliferative therapy for HIV cure: a compound interest
 approach. *Scientific Reports*. 2017;7(4011). doi:10.1038/s41598-017-04160-3.
- Hill AL, Rosenbloom DIS, Nowak MA, et al. Insight into treatment of HIV infection from viral dynamics
 models. *Immunological Reviews*. 2018;285(1):9–25. doi:https://doi.org/10.1111/imr.12698.
- Prague M, Gerold JM, Balelli I, et al. Viral rebound kinetics following single and combination immunother apy for HIV/SIV. *bioRxiv*. 2019;doi:10.1101/700401.
- Huenecke S, Behl M, Fadler C, et al. Age-matched lymphocyte subpopulation reference values in child hood and adolescence: application of exponential regression analysis. *European journal of haematology*.
 2008;80(6):532–539.

HIV resurgence in infants on ART 19

- ⁴⁰⁰ 14. Schröter J, Anelone AJN, de Boer RJ. Quantification of CD4 recovery in early-treated infants living with
 ⁴⁰¹ HIV. *In revision*. 2021;.
- Kuhn L, Strehlau R, Shiau S, et al. Early antiretroviral treatment of infants to attain HIV remission. *EClini- calMedicine*. 2020;18. doi:10.1016/j.eclinm.2019.100241.
- Morris SE, Dziobek-Garrett L, Yates AJ. ushr: Understanding suppression of HIV in R. *BMC Bioinformatics*.
 2020;21(52). doi:10.1186/s12859-020-3389-x.
- Ke R, er Cong M, Li D, et al. On the Death Rate of Abortively Infected Cells: Estimation from Simian-Human
 Immunodeficiency Virus Infection. *Journal of Virology*. 2017;91(18):e00352–17. doi:10.1128/JVI.00352-17.
- 18. Ramratnam B, Bonhoeffer S, Binley J, et al. Rapid production and clearance of HIV-1 and hepatitis C
 virus assessed by large volume plasma apheresis. *Lancet*. 1999;354(9192):1782–1785. doi:10.1016/S01406736(99)02035-8.
- ⁴¹¹ 19. Payne H, Lawrie D, Nieuwoudt M, et al. Comparison of Lymphocyte Subset Populations in Children From
 ⁴¹² South Africa, US and Europe. *Frontiers in Pediatrics*. 2020;8:406. doi:10.3389/fped.2020.00406.
- 413 20. Mould D, Upton R. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Devel 414 opment Part 2: Introduction to Pharmacokinetic Modeling Methods. *CPT: Pharmacometrics & Systems* 415 *Pharmacology*. 2013;2(4):38. doi:10.1038/psp.2013.14.
- 416 21. Monolix version 2020R1. Antony, France: Lixosoft SAS; 2020. Available from: http://lixoft.com/
 417 products/monolix/.
- ⁴¹⁸ 22. Castro M, de Boer RJ. Testing structural identifiability by a simple scaling method. *PLOS Computational* ⁴¹⁹ *Biology*. 2020;16(11):1–15. doi:10.1371/journal.pcbi.1008248.
- A20 23. R Development Core Team. R: A Language and Environment for Statistical Computing; 2008. Available
 from: http://www.r-project.org.
- 422 24. Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R: Package deSolve. *Journal of Statistical* 423 Software. 2010;33(9):1–25. doi:10.18637/jss.v033.i09.
- 424 25. Wickham H, Averick M, Bryan J, et al. Welcome to the Tidyverse. *Journal of Open Source Software*.
 425 2019;4(43):1686. doi:10.21105/joss.01686.
- 426 26. Wilke CO. cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2'; 2020. Available from:
 https://CRAN.R-project.org/package=cowplot.
- Pedersen TL. patchwork: The Composer of Plots; 2020. Available from: https://CRAN.R-project.org/
 package=patchwork.
- 28. Callaway D, Perelson A. HIV-1 infection and low steady state viral loads. *Bull Math Biol*. 2002;64(1):29–64.
 doi:10.1006/bulm.2001.0266.
- 432 29. Kuhn L, Paximadis M, Da Costa Dias B, et al. Predictors of cell-associated HIV-1 DNA over one year in
 433 very early treated infants. *Clinical Infectious Diseases*. 2021;ciab586. doi:10.1093/cid/ciab586.

HIV resurgence in infants on ART 20

434 30. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: viron clear435 ance rate, infected cell life-span, and viral generation time. *Science*. 1996;271(5255):1582–1586.
436 doi:10.1126/science.271.5255.1582.

- 437 31. Luzuriaga K, Wu H, McManus M, et al. Dynamics of human immunodeficiency virus type 1 replication in
 438 vertically infected infants. *J Virol*. 1999;73(1):362–367.
- 439 32. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in
 HIV-1 infection. *Nature*. 1997;387(6629):183–188.
- 33. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 Infection Is Associated with Preferential
 Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract. *Journal of Experimental Medicine*. 2004;200(6):761–770.
- ⁴⁴⁴ 34. Pan X, Baldauf HM, Keppler OT, et al. Restrictions to HIV-1 replication in resting CD4+ T lymphocytes.
 ⁴⁴⁵ *Cell Res.* 2013;23(7):876–85. doi:10.1038/cr.2013.74.
- 35. Zack JA, Kim SG, Vatakis DN. HIV restriction in quiescent CD4+ T cells. *Retrovirology*. 2013;10:37.
 doi:10.1186/1742-4690-10-37.

Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy

Sinead E. Morris¹, Renate Strehlau², Stephanie Shiau^{3,4}, Elaine J. Abrams^{4,5,6}, Caroline T. Tiemessen⁷, Louise Kuhn^{3,4}, Andrew J. Yates¹, on behalf of the EPIICAL Consortium and the LEOPARD study team

¹Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA

²Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

³Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA

⁴Department of Epidemiology, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁵ICAP at Columbia University, Mailman School of Public Health, Columbia University Medical Center, New York, NY, USA

⁶Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University Medical Center, New York, NY, USA

⁷Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services, and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Supplementary Information

Additional information on infant adherence

At each study visit, the infant's caregiver provided additional information for a questionnaire taken by the attending physician. Caregivers were asked if any doses had been missed since the previous visit and, if so, how many. They were also asked about any challenges administering the medication, including drug tolerance issues (e.g. if the infant spit up the medicine and repeat doses were required).

This information was a valuable supplement to estimates of adherence calculated from the amount of medication returned at the visit, given that these were often missing (due to leftover medication spilling or being left at home). If a particular adherence estimate was missing, we checked the corresponding questionnaire; if the physician noted serious adherence concerns for that drug, such as a series of missed doses, adherence was labeled as 'poor'. See Fig S10 for the resulting time series.

Model

Starting with the original set of equations

$$\frac{dT}{dt} = \theta(t,T) - (1-\epsilon_1)\beta VT$$
$$\frac{dI}{dt} = \rho(1-\epsilon_1)\beta VT - dI + a$$
$$\frac{dV}{dt} = (1-\epsilon_2)pI - cV,$$

we assume that viral dynamics occur on a faster timescale than those of CD4 T cells, i.e. dV/dt = 0. This gives $I = cV/(1 - \epsilon_2)p$, and we can rewrite the above equations as

$$\frac{dT}{dt} = \theta(t,T) - (1-\epsilon_1)\beta VT$$
$$\frac{c}{(1-\epsilon_2)p}\frac{dV}{dt} = \rho(1-\epsilon_1)\beta VT - d\frac{cV}{(1-\epsilon_2)p} + a,$$

i.e.

$$\frac{dT}{dt} = \theta(t,T) - (1-\epsilon_1)\beta VT$$
$$\frac{dV}{dt} = \rho \frac{(1-\epsilon_2)p}{c}(1-\epsilon_1)\beta VT - dV + a \frac{(1-\epsilon_2)p}{c}.$$

Setting $\beta_0 = (1 - \epsilon_1)\beta$ and $\bar{c} = (1 - \epsilon_2)p/c$ then gives the reduced system,

$$\begin{aligned} \frac{dT}{dt} &= \theta(t,T) - \beta_0 VT \\ \frac{dV}{dt} &= \rho \bar{c} \beta_0 VT - dV + a \bar{c} \end{aligned}$$

Structural Identifiability

We explore the structural identifiability of the equations using the approach of Castro and de Boer (2020) [1]. First, we define scaling factors for all parameters we want to estimate, i.e. $u_{\beta_0}, u_{\bar{c}}, u_d, u_a$ and $u_{\bar{r}}$. The scaling factors for all fixed parameters are equal to one. Similarly, since both V and T are observed, we do not need to define any variable scaling factors.

Next, we equate all functionally independent terms in our equations that contain these parameters to their scaled counterparts:

$$\begin{split} u_{\bar{r}}\bar{r} &= \bar{r} & \Leftrightarrow & u_{\bar{r}} = 1 \\ -u_{\beta_0}\beta_0 VT &= -\beta_0 VT & \Leftrightarrow & u_{\beta_0} = 1 \\ \rho u_{\bar{c}}\bar{c}u_{\beta_0}\beta_0 VT &= \rho\bar{c}\beta_0 VT & \Leftrightarrow & u_{\bar{c}} = 1 \text{ since } u_{\beta_0} = 1 \\ -u_d dV &= -dV & \Leftrightarrow & u_d = 1 \\ u_a a u_{\bar{c}}\bar{c} = a\bar{c} & \Leftrightarrow & u_a = 1 \text{ since } u_{\bar{c}} = 1. \end{split}$$

Since all scaling factors have solution equal to 1, all estimated parameters are identifiable. Note that we assume r is identifiable if \bar{r} is identifiable and T_R is fixed.

Nonlinear Mixed Effects Modeling in Monolix

We fit the following system of equations in Monolix,

$$\frac{dT}{dt} = -b_1 b_0 e^{b_1 t} + \bar{r} - \beta_0 V T$$
$$\frac{dV}{dt} = \rho \bar{c} \beta_0 V T - dV + a \bar{c}.$$

All VL observations below the detection threshold of 20 copies ml⁻¹ are treated as censored values. In line with previous pharmacokinetic and viral dynamics modeling, we assumed both V(t) and T(t) were lognormally distributed with combined error models, i.e. for variable $X_i(t)$, the residual error is expressed as the sum of a constant term and a term proportional to $X_i(t)$ ('combined1' in Monolix) [2–4].

We fix b_0 , b_1 and ρ across infants to the values given in Table 1. Initially we fix $T_R = 190$ days across all infants, but subsequently explore fits when this value is varied, and when it is freely estimated. All other parameters were estimated and assumed to have both fixed and random effects. Guided by exploratory fits, each estimated parameter was assumed to follow a lognormal distribution, with the exception of a which followed a logit-normal distribution between 0 and 0.1, and r which followed a normal distribution, and T_R which also followed a normal distribution (when estimated). Initial estimates for all population parameters are given in Table S3. Initial estimates for the residual error models were kept at their default values. Following exploratory fits, we allowed for a correlation between β_0 and d, but assumed all other parameters were independent.

Supplementary Figures and Tables

SexMale59CategoricalFemale63Female63PretermYes88CategoricalNo103Categorical103Delivery modeNormal vaginal delivery Caesarean section87CategoricalBirth weight (g)<2500 2500+29 2500+ContinuousAge at ART initiation (days)<2 2-14 14+49CategoricalPre-treatment CD4 percentage 35+<35 35+33 61 Not recordedContinuousMother's viral load (copies ml ⁻¹) 1000+<350 350+61 61ContinuousMother's CD4 count (cells μl^{-1}) 25+<350 350+61 61ContinuousMother's CD4 percent 25+<25 25+77 45ContinuousMaternal prenatal ART history UnknownNone 1<350 11 11 11 1137 25CategoricalBreastfeedingSome None96Categorical	Covariate	Group	ui alla N	Variable treatment
SexMale Female59Categorical CategoricalPretermYes No88Categorical 	Sovuriate	Sloup	11	
Female63PretermYes No88 103Categorical NoDelivery modeNormal vaginal delivery Caesarean section87 35Categorical 29 290Birth weight (g) 2500 29029 2500+Continuous 291Age at ART initiation (days) 2-14 14+ 22 14+49 17Categorical 200Pre-treatment CD4 percentage 35+ Not recorded33 35+ 1000+Continuous 22Mother's viral load (copies ml ⁻¹) 1000+32 350+Continuous 21Mother's CD4 count (cells μl^{-1}) 25+ 255 25+61 41Continuous 25Mother's CD4 percent 1000+25 25+Continuous 26Continuous 26Mother's CD4 percent 1000+25 25+Continuous 26Categorical 27 25+Maternal prenatal ART history 1nitiated 12+ weeks into pregnancy 1nitiated 12+ weeks into pregnancy 18 1nitiated 12+ weeks into pregnancy25 41 41 11BreastfeedingSome None96 40Categorical	Sex	Male	59	Categorical
PretermYes No88 103CategoricalDelivery modeNormal vaginal delivery Caesarean section87 85CategoricalBirth weight (g)<2500 2500+29 2500+ContinuousAge at ART initiation (days)<2 2-14 14+49 56CategoricalPre-treatment CD4 percentage<35 35+ Not recorded33 25+ 1000+ContinuousMother's viral load (copies ml-1) 1000+<1000 1000+32 350+ContinuousMother's CD4 count (cells µl-1) 25+<350 350+61 61ContinuousMother's CD4 percent 25+<25 25+<77 45ContinuousMaternal prenatal ART history Initiated 12+ weeks into pregnancy Initiated 12+ weeks into pregnancy 18 Unknown36 46CategoricalBreastfeedingSome None36 46Categorical		Female	63	
PretermYes88CategoricalNo103103Delivery modeNormal vaginal delivery Caesarean section87CategoricalBirth weight (g) ~ 2500 29Continuous $2500+$ 93CategoricalAge at ART initiation (days) ~ 2 49Categorical ~ 2 49Categorical2-1456 $14+$ 175614+17Pre-treatment CD4 percentage ~ 35 33Continuous $35+$ 6102855+Mother's viral load (copies ml ⁻¹) ~ 1000 32Continuous $1000+$ 9050+61ContinuousMother's CD4 percent ~ 25 77Continuous $25+$ 455777ContinuousMaternal prenatal ART historyNone25Categorical 11 11 111212BreastfeedingSome96Categorical				
No103Delivery modeNormal vaginal delivery Caesarean section87 35CategoricalBirth weight (g) ~ 2500 $2500+$ 29 30ContinuousAge at ART initiation (days) ~ 2 $2-14$ $14+$ 49 56CategoricalPre-treatment CD4 percentage ~ 35 $35+$ Not recorded33 20ContinuousMother's viral load (copies ml ⁻¹) < 1000 $1000+$ 32 $350+$ ContinuousMother's CD4 count (cells μl^{-1}) < 350 $25+$ 61 41ContinuousMother's CD4 percent < 25 $25+$ 77 45ContinuousMother's CD4 percent < 25 $25+$ 77 45CategoricalMaternal prenatal ART historyNone Initiated 12+ weeks into pregnancy Initiated <12 weeks into pregnancy Imitiated <12 weeks into pr	Preterm	Yes	88	Categorical
Delivery modeNormal vaginal delivery Caesarean section87 35CategoricalBirth weight (g)<2500		No	103	
Delivery modeNormal vaginal delivery Caesarean section87Categorical CategoricalBirth weight (g) <2500 29Continuous $2500+$ 93CategoricalAge at ART initiation (days) <2 49Categorical $2-14$ 5629Categorical $14+$ 177CategoricalPre-treatment CD4 percentage <35 33 Continuous $35+$ 61ContinuousNother's viral load (copies ml ⁻¹) <1000 32 Continuous $1000+$ 90ContinuousMother's CD4 count (cells μl^{-1}) <350 61 Continuous $350+$ 61ContinuousMaternal prenatal ART historyNone 25 CategoricalMaternal prenatal ART historyNone 25 CategoricalBreastfeedingSome 96 CategoricalBreastfeedingSome 96 Categorical				
Caesarean section 35 Birth weight (g) <2500	Delivery mode	Normal vaginal delivery	87	Categorical
Birth weight (g)2500 2500+29 93Continuous 93Age at ART initiation (days)<2 2-14 14+49 56 14+Categorical 61Pre-treatment CD4 percentage<35 35+ Not recorded33 61 28Continuous 61Mother's viral load (copies ml^-1)<1000 1000+32 90Continuous 61Mother's CD4 count (cells µl^-1) 25+<350 350+61 61Continuous 61Mother's CD4 percent 25+<25 25+77 45Continuous 61Maternal prenatal ART history Initiated 12+ weeks into pregnancy Initiated 12+ weeks into pregnancy 18 Unknown350 41 11Categorical 61BreastfeedingSome None96 26Categorical		Caesarean section	35	
Birth weight (g) <2500 29 Continuous 2500+ 93 Age at ART initiation (days) <2				
Age at ART initiation (days)<249Categorical214565614+17Pre-treatment CD4 percentage<35	Birth weight (g)	<2500	29	Continuous
Age at ART initiation (days) <2		2500+	93	
Age at ART initiation (days) <2				
2-14 56 14+ 17 Pre-treatment CD4 percentage <35	Age at ART initiation (days)	<2	49	Categorical
14+17Pre-treatment CD4 percentage<35		2-14	56	
Pre-treatment CD4 percentage<3533Continuous35+6161Not recorded28Mother's viral load (copies ml ⁻¹)<1000		14+	17	
Pre-treatment CD4 percentage<3533Continuous35+61128Mother's viral load (copies ml^-1)<1000				
$\begin{array}{ c c c c c } 35+ & 61 \\ Not recorded & 28 \end{array}$ $\begin{array}{ c c c c } Mother's viral load (copies ml^{-1}) & <1000 & 32 \\ 1000+ & 90 \end{array} & \begin{array}{ c c } Continuous \\ 1000+ & 90 \end{array}$ $\begin{array}{ c c } Mother's CD4 count (cells $\mu l^{-1}) & <350 & 61 \\ 350+ & 61 \end{array} & \begin{array}{ c } Continuous \\ 350+ & 61 \end{array}$ $\begin{array}{ c } Mother's CD4 percent & <25 & 77 \\ 25+ & 45 \end{array} & \begin{array}{ c } Continuous \\ 25+ & 45 \end{array}$ $\begin{array}{ c } Maternal prenatal ART history & None & 25 \\ Initiated 12+ weeks into pregnancy & 37 \\ Initiated <12 weeks into pregnancy & 41 \\ Initiated before pregnancy & 18 \\ Unknown & 1 \end{array}$ $\begin{array}{ c } Breastfeeding & Some & 96 \\ None & 26 \end{array} & \begin{array}{ c } Categorical \\ Categorical \\ \end{array}$	Pre-treatment CD4 percentage	<35	33	Continuous
Not recorded28Mother's viral load (copies ml ⁻¹)<1000		35+	61	
Mother's viral load (copies ml^-1)<100032Continuous1000+9090Mother's CD4 count (cells μl^{-1})<350		Not recorded	28	
Mother's viral load (copies ml^-1)<100032Continuous1000+901000+90Mother's CD4 count (cells μl^{-1})<350				·
1000+90Mother's CD4 count (cells μl ⁻¹)<350	Mother's viral load (copies ml^{-1})	<1000	32	Continuous
Mother's CD4 count (cells μl^{-1})<35061Continuous350+61Mother's CD4 percent<25		1000+	90	
Mother's CD4 count (cells μl^{-1})<35061Continuous350+61Mother's CD4 percent<25				
350+61Mother's CD4 percent<25	Mother's CD4 count (cells μl^{-1})	<350	61	Continuous
Mother's CD4 percent<25 25+77 45Continuous 25Maternal prenatal ART historyNone Initiated 12+ weeks into pregnancy Initiated <12 weeks into pregnancy 41 Initiated before pregnancy 18 Unknown25 41CategoricalBreastfeedingSome None96 26Categorical		350+	61	
Mother's CD4 percent<2577Continuous25+4577ContinuousMaternal prenatal ART historyNone25CategoricalInitiated 12+ weeks into pregnancy3711Initiated <12 weeks into pregnancy				·
25+45Maternal prenatal ART historyNone25CategoricalInitiated 12+ weeks into pregnancy37Initiated <12 weeks into pregnancy	Mother's CD4 percent	<25	77	Continuous
Maternal prenatal ART historyNone25CategoricalInitiated 12+ weeks into pregnancy37Initiated <12 weeks into pregnancy		25+	45	
Maternal prenatal ART historyNone25CategoricalInitiated 12+ weeks into pregnancy37Initiated <12 weeks into pregnancy				L
Initiated 12+ weeks into pregnancy37Initiated 12 weeks into pregnancy41Initiated before pregnancy18Unknown1BreastfeedingSome96None26	Maternal prenatal ART history	None	25	Categorical
Initiated <12 weeks into pregnancy		Initiated 12+ weeks into pregnancy	37	
Initiated before pregnancy 18 Unknown 1 Breastfeeding Some None 26		Initiated <12 weeks into pregnancy	41	
Unknown 1 Breastfeeding Some 96 Categorical None 26		Initiated before pregnancy	18	
Breastfeeding Some 96 Categorical None 26		Unknown	1	
Breastfeeding Some 96 Categorical None 26				1
None 26	Breastfeeding	Some	96	Categorical
	U U	None	26	

Table C1. C. f the aliminal accomintation in alu dad in . . . 1.

Table S2: Comparing models with T_R fixed across all infants. The AIC difference for model *i* was calculated as AIC_{*i*} – AIC_{*min*}, where AIC_{*min*} is the minimum AIC value across all models. The model with zero difference is the model with lowest AIC and thus is the most strongly favored.

_

Fixed value of T_R (days)	AIC difference
170	38.6
190	34.8
210	25.9
215	23.6
220	10.5
223	8.3
225	0.0
227	24.4
230	13.2
240	30.3
250	22.8
270	30.8
300	43.2

Parameter	Distribution	Fixed effect	Standard Deviation	
			of Random Effects	
β_0	Lognormal	1×10^{-6}	0.1	
\bar{c}	Lognormal	100	1	
d	Lognormal	0.3	0.1	
a	Logitnormal (0–0.1)	0.01	0.1	
r	Normal	9	0.25	
T_R^*	Normal	225	2	
T_A^*	Normal	365	2	
T_0	Lognormal	3500	1	
V_0	Lognormal	10,000	1	

 Table S3: Initial estimates for the population parameters in Monolix.

*when estimated



Figure S1: The standard model for adult CD4 T cell dynamics does not capture infant data. Each panel represents a different infant, points represent the data, and solid lines are the model fits. Here $\theta(t, T) = \lambda - d_T T$, with λ and d_T assumed to have lognormal distributions. Initial estimates for the population mean were 1000 cells μ l⁻¹ day⁻¹ and 0.25 day⁻¹, respectively, and for the standard deviation were 1 and 0.1, respectively. The nonlinear mixed effects fitting procedure was as described in the main text.



Change in estimated value — -20% — -10% — 0% — 10% — 20%

Figure S2: Sensitivity of VL predictions to model parameters. Each fixed (A) or estimated (B) parameter was varied within 20% of its original value while keeping all other parameters at their original values. Original values for the estimated parameters were the population-level means from the best-fit model. Note that predictions for ρ do not include 10% and 20% increases as these are biologically unrealistic (i.e. a fraction > 1).



Change in estimated value — -20% — -10% — 0% — 10% — 20%

Figure S3: Sensitivity of CD4 T cell predictions to model parameters. Each fixed (A) or estimated (B) parameter was varied within 20% of its original value while keeping all other parameters at their original values. Original values for the estimated parameters were the population-level means from the best-fit model. Note that predictions for ρ do not include 10% and 20% increases as these are biologically unrealistic (i.e. a fraction > 1).



Figure S4: **Relative contribution of factors driving an increase in productively infected cells.** Each panel represents an infant, and red shaded regions show their VL scaled by its maximum value.



Figure S5: VL and CD4 T cell dynamics influence the time at which reactivation contributes most to productively infected cell growth. Each point represents a different infant with respect to the time at which reactivation became the major contributor to productively infected cell growth and the time at which: (A) their VL started increasing (if applicable); (B) their VL finished increasing (if applicable); and (C) their CD4 T cell recovery plateaued (T_R). Correlations are 0.45, 0.71 and 0.29, respectively, and p < 0.05 in all cases. Note that the correlation in (C) is reduced to a trend (p = 0.05) when the infant with the lowest T_R is removed.





Figure S7: **Correlations between estimated parameters.** The colour scale shows the strength of the correlation; those with p-values greater than a significance threshold of 0.05 are crossed out. p-values were adjusted using the Benjamini-Hochberg correction. The strong correlation between β_0 and d was included in the nonlinear mixed effects model framework.



Figure S8: Longer duration of maternal ART is associated with greater VL production to decay ratios. The ratio is given by $\bar{c} = (1 - \epsilon_2)p/c$, in copies ml⁻¹ cell⁻¹. Each point represents a different infant. Significance levels are $p < 0.01(^{**})$; $p < 0.001(^{***})$.



Figure S9: LPV/r adherence estimated from returned medication. Each line represents a different infant.



Figure S10: **Reported adherence trajectories.** Adherence estimates greater than 90% were labeled 'good'; and all others 'poor'. Each panel is a different infant.

References

- 1. Castro M, de Boer RJ. Testing structural identifiability by a simple scaling method. *PLOS Computational Biology*. 2020;16(11):1–15. doi:10.1371/journal.pcbi.1008248.
- 2. Prague M, Gerold JM, Balelli I, et al. Viral rebound kinetics following single and combination immunotherapy for HIV/SIV. *bioRxiv*. 2019;doi:10.1101/700401.
- Monolix version 2020R1. Antony, France: Lixosoft SAS; 2020. Available from: http://lixoft.com/products/ monolix/.
- Mould D, Upton R. Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development Part
 Introduction to Pharmacokinetic Modeling Methods. *CPT: Pharmacometrics & Systems Pharmacology*. 2013;2(4):38. doi:10.1038/psp.2013.14.